Supreme Court Declined Antitrust Review of Vizient
Healthcare providers and suppliers should note how market definition requirements shape the success of antitrust litigation.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Should the federal government impose stricter antitrust regulations on group purchasing organizations?
The U.S. Supreme Court denied a petition to review a lower court ruling in an antitrust case against Vizient Inc. The case alleged the company used anticompetitive practices to lock in hospital customers, but failed to survive judicial scrutiny.
Why it matters
The case highlights the critical importance of precisely defining a relevant market when alleging monopolistic behavior in healthcare supply chains. Plaintiffs failed to meet this threshold, allowing the lower court's decision in favor of Vizient Inc. to stand.
The Supreme Court rejected one petition regarding alleged anticompetitive practices by Vizient Inc. The refusal upholds a lower court finding that the medical tape supplier failed to define the relevant monopolized market.
The players
Vizient Inc.
A healthcare performance improvement company that provides data and analytics to hospital systems.
U.S. Supreme Court
The highest federal judicial body that determines whether to hear appeals from lower court rulings.
The details
The litigation hinged on whether Vizient Inc. unfairly leveraged its position to lock in hospital customers, effectively excluding competitors. Lower courts ultimately found the claims insufficient because the plaintiff did not adequately define the scope of the relevant market. By refusing to grant certiorari, the Supreme Court leaves this precedent intact, reinforcing the high burden of proof required for market definition in antitrust claims.
Timeline
October 5, 2026: The Supreme Court refused to review the antitrust case.
Market Landscape
The ruling follows a pattern of strict judicial enforcement regarding antitrust pleading standards in complex markets. It reinforces the precedent that vague market definitions are insufficient to proceed with litigation against large entities.
Businesses alleging anticompetitive behavior must ensure their legal counsel can provide a rigorous, data-backed definition of the relevant market. Operators should view this as a signal that the courts remain skeptical of broad monopolization claims lacking specific economic proof.
The takeaway
This case underscores the high barrier to entry for proving antitrust claims in concentrated markets like medical supplies. Operators should monitor how their legal counsel structures market definitions when evaluating potential anticompetitive threats from suppliers or vendors.
Further reading
For more on industry regulatory trends, visit the Healthcare section.
Source note: This article includes information reported by Law360.
Live Poll
Should the federal government impose stricter antitrust regulations on group purchasing organizations?
